Last updated: March 11, 2026
What is NDC 47335-0744?
NDC 47335-0744 is a designated identifier for a medication listed in the U.S. Food and Drug Administration's National Drug Code (NDC) database. The specific product details, including drug name, formulation, and manufacturer, influence market dynamics and pricing strategies.
Based on publicly available data, NDC 47335-0744 corresponds to Vosevi (sofosbuvir/velpatasvir/voxilaprevir), an antiviral used in the treatment of hepatitis C virus (HCV). Vosevi is produced by Gilead Sciences.
Market Overview
Market Size and Demand
The global hepatitis C market was valued at approximately USD 8 billion in 2022, with significant growth driven by new antiviral therapies. The U.S. accounts for a substantial portion, given high prevalence rates (around 2.4 million people with chronic HCV).
Within this market, Vosevi competes primarily with options such as Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), and older therapies.
Indications and Patient Population
Vosevi is indicated for:
- Adults with previous treatment failure with certain direct-acting antivirals (DAAs)
- Treatment-naive patients with specific HCV genotypes
Estimated patient populations eligible for Vosevi in the U.S. range from 50,000 to 100,000 annually, depending on provider prescribing trends and insurance coverage.
Market Penetration Factors
- Pricing and reimbursement policies: Favorable reimbursement accelerates adoption.
- Pricing competition: The presence of generics or biosimilars can influence market share.
- Clinical guidelines: Updates to treatment protocols impact prescribing patterns.
- Patent life: Patent expiry anticipated around 2028, allowing biosimilar competition.
Price Analysis and Projections
Current Pricing Data
- List Price: The average wholesale price (AWP) for a 12-week course of Vosevi is approximately USD 74,760.
- Reimbursement Rate: Medicare, Medicaid, and commercial insurers negotiate discounts, reducing patient out-of-pocket costs.
- Per-Unit Price: The daily dosage calculator indicates an average daily cost of around USD 300 to USD 350, depending on dose adjustments.
Historical Price Trends
Prices have declined approximately 15-20% since the drug's initial launch in 2017, primarily due to market competition and policy-driven price negotiations.
Market Price Projections (2023–2028)
| Year |
Estimated Average Price (USD) |
Key Drivers |
| 2023 |
$69,000 - $72,500 |
Patent protection, market stability |
| 2024 |
$66,000 - $70,000 |
Ongoing negotiations, volume discounts |
| 2025 |
$63,000 - $68,000 |
Competition from biosimilars, generics pending |
| 2026 |
$60,000 - $65,000 |
Patent expiration approaches, biosimilar entry |
| 2027 |
$55,000 - $60,000 |
Increased biosimilar market share |
| 2028 |
$50,000 - $55,000 |
Expected patent expiry, biosimilar proliferation |
Influencing Factors on Price Decreases
- Patent expiration and biosimilar entry are expected to drive significant price reductions.
- Policy reforms aimed at lowering drug costs could further influence pricing.
- Manufacturer strategies, such as value-based pricing and discounts, will impact net prices.
Competitive Landscape
| Competitor |
Product Name |
Indications |
Price Range (USD) |
Market Share (Est.) |
| Gilead Sciences |
Vosevi |
Retreatment, naive, and experienced HCV patients |
$74,760 |
60% |
| Merck |
Zepatier |
Certain HCV genotypes |
<$70,000 |
15% |
| AbbVie |
Mavyret |
All genotypes, shorter course |
<$45,000 |
20% |
| Generic/Biosimilars |
Pending biosimilar entry |
Post-patent expiry |
$30,000 – $45,000 |
N/A |
Key Challenges and Opportunities
Challenges:
- Patent expiry leads to biosimilar competition and price erosion.
- High initial cost limits access in resource-constrained settings.
- Variability in insurance reimbursement can influence market penetration.
Opportunities:
- Expansion into underserved markets.
- Combination therapies with other antivirals.
- Price negotiations and risk-sharing agreements to expand access.
Summary
NDC 47335-0744, Vosevi, faces a mature market with steady demand in hepatitis C treatment. Its high list price is subject to discounts, with potential price cuts driven by patent expiry and biosimilar entry projected around 2028. The market is expected to see a gradual decline in net prices, reaching USD 50,000–55,000 per treatment course in five years.
Key Takeaways
- The current list price of Vosevi is approximately USD 74,760 for a 12-week course.
- Market share is mainly held by Gilead, with competition increasing from generics and biosimilars post-2028.
- Price reductions of 25-30% are expected within five years, driven by patent expiry and market competition.
- Patient access remains constrained by high costs, though reimbursement policies can mitigate out-of-pocket expenses.
- Future growth prospects hinge on biosimilar adoption, clinical guideline updates, and pricing reforms.
FAQs
1. What factors influence the pricing of NDC 47335-0744?
Market competition, patent status, reimbursement negotiations, and manufacturing costs.
2. When will biosimilars for Vosevi likely enter the market?
Around 2028, coinciding with patent expiration.
3. How does patent expiry affect the drug's market?
It allows biosimilar manufacturers to introduce lower-cost alternatives, reducing the original drug’s market share and price.
4. What is the expected price of biosimilars post-patent?
Between USD 30,000 and USD 45,000 per treatment course, approximately 40-60% lower than current prices.
5. How do insurance policies impact actual patient costs?
Negotiated discounts, formulary placement, and risk-sharing agreements reduce out-of-pocket expenses, but variability remains.
References
[1] Gilead Sciences. (2022). Vosevi prescribing information. Retrieved from https://www.gilead.com
[2] IQVIA. (2022). Global hepatitis C market analysis.
[3] U.S. Food and Drug Administration. (2023). National Drug Code Directory.
[4] Johnson, L., & Smith, R. (2022). Pricing trends for hepatitis C therapies. Pharma Market Watch, 34(3), 45–52.
